ZALTRAP SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

AFLIBERCEPT

Dostopno od:

SANOFI-AVENTIS CANADA INC

Koda artikla:

L01XX44

INN (mednarodno ime):

AFLIBERCEPT

Odmerek:

100MG

Farmacevtska oblika:

SOLUTION

Sestava:

AFLIBERCEPT 100MG

Pot uporabe:

INTRAVENOUS

Enote v paketu:

4ML/3X4ML

Tip zastaranja:

Prescription

Terapevtsko območje:

ANTINEOPLASTIC AGENTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0154950002; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2020-07-13

Lastnosti izdelka

PRODUCT MONOGRAPH
Pr
ZALTRAP
™
Aflibercept
Concentrate for solution for infusion, 25 mg/mL
100 mg and 200 mg vials
Antineoplastic agent
ATC code: L01XX44
sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval, Québec H7V 0A3
Date of Preparation:
August 3, 2016
Submission Control No.: 196179
Date of Approval: August 5, 2016
_ _
_ _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL INFORMATION
..........................................................................27
CLINICAL TRIALS
..........................................................................................................28
TOXICOLOGY
............